Download PDF
Thromb Haemost 1989; 61(01): 117-121
DOI: 10.1055/s-0038-1646538
Original Article
Schattauer GmbH Stuttgart

Haemostatic Effects of Recombinant Human Erythropoietin in Chronic Haemodialysis Patients

Chris van Geet
The Centre for Thrombosis and Vascular Research and the Department of Nephrology, University of Leuven, Belgium
,
Didier Hauglustaine
The Centre for Thrombosis and Vascular Research and the Department of Nephrology, University of Leuven, Belgium
,
Luc Verresen
The Centre for Thrombosis and Vascular Research and the Department of Nephrology, University of Leuven, Belgium
,
Marleen Vanrusselt
The Centre for Thrombosis and Vascular Research and the Department of Nephrology, University of Leuven, Belgium
,
Jos Vermylen
The Centre for Thrombosis and Vascular Research and the Department of Nephrology, University of Leuven, Belgium
› Author Affiliations
Further Information

Publication History

Received 16 May 1988

Accepted after revision 26 September 1988

Publication Date:
24 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Recombinant human erythropoietin was administered for up to 40 weeks to nine patients on chronic haemodialysis. From the third week of administration onwards, not only haemoglobin and haematocrit but also the platelet count rose, the latter, however, transiently. Subnormal platelet aggregation before therapy also improved transiently and in parallel with the erythropoietin dosage. The bleeding time normalized in almost all patients. There were no major side-effects. We conclude that recombinant erythropoietin improves haemostasis in chronic haemodialysis patients by increasing the haematocrit and in addition transiently enhances platelet number and function.

Key words

Recombinant human erythropoietin - Chronic haemodialysis patients - Bleeding time - Platelet
 

  • References

  • 1 Winearls CG, Pippard MJ, Downing MR, Oliver DO, Reid C, Cotes PM. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986; 2: 1175-1178
    PubMedGoogle Scholar
  • 2 Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med 1987; 316: 73-78
    CrossrefPubMedGoogle Scholar
  • 3 Bommer J, Müller-Bühl E, Ritz E, Eifert J. Recombinant human erythropoietin in anaemic patients on haemodialysis. Lancet 1987; 1: 392
    PubMedGoogle Scholar
  • 4 Moia M, Vizzotto L, Cattaneo M, Mannucci PM, Casati S, Ponticelli C. Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin. Lancet 1987; 2: 1227-1229
    PubMedGoogle Scholar
  • 5 Casati S, Passerini P, Campise MR, Graziani G, Cesana B, Perisic M, Ponticelli C. Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. Br Med J 1987; 295: 1017-1020
    CrossrefPubMedGoogle Scholar
  • 6 Nieuwenhuis HK, Sixma J. Bleeding time measurements. In: Measurements of Platelet Function Methods in Hematology, Vol. 8. Harker LA, Zimmermann TS. (eds) Churchill Livingstone; Edinburgh: 1983. pp 26-45
    Google Scholar
  • 7 Gresele P, Amout J, Janssens W, Deckmyn H, Lemmens J, Vermylen J. BM 13.177, a selective blocker of platelet and vessel wall thromboxane receptors, is active in man. Lancet 1984; 1: 991-994
    PubMedGoogle Scholar
  • 8 Allain JP, Cooper HA, Wagner RH, Brinkhous KM. Platelets fixed with paraformaldehyde: a new reagent for assay of von Willebrand factor and platelet aggregating factor. J Lab Clin Med 1975; 85: 318-328
    PubMedGoogle Scholar
  • 9 Jubelirer SJ. Hemostatic abnormalities in renal disease. Am J Kidney Dis 1985; 5: 219-225
    CrossrefPubMedGoogle Scholar
  • 10 Steiner RW, Coggins C, Carvalho AC A. Bleeding time in uremia: a useful test to assess clinical bleeding. Am J Hematol 1979; 7: 107-117
    CrossrefPubMedGoogle Scholar
  • 11 Livio M, Marchesi D, Remuzzi G, Gotti E, Mecca G, de Gaetano G. Uraemic bleeding: role of anaemia and beneficial effect of red cell transfusions. Lancet 1982; 2: 1013-1015
    PubMedGoogle Scholar
  • 12 Soltani G, Fernandez F, Pris J, Boneu B. Allongement du temps de saignement au cours des anemies severes. Presse Med 1986; 15: 745-747
    PubMedGoogle Scholar
  • 13 Fernandez F, Goudable C, Sie P, Ton-That H, Durand D, Suc JM, Boneu B. Low haematocrit and prolonged bleeding time in uraemic patients: effect of red cell transfusions. Br J Haematol 1985; 59: 139-148
    CrossrefPubMedGoogle Scholar
  • 14 Turitto VT, Weiss HJ. Red blood cells: their dual role in thrombus formation. Science 1980; 207: 541-543
    CrossrefPubMedGoogle Scholar
  • 15 Tśao C, Lo R, Raymond J. Critical importance of citrate-blood ratio in platelet aggregation studies. Am J Clin Pathol 1976; 65: 518-522
    CrossrefPubMedGoogle Scholar
  • 16 Clark DA, Dessypris EN. Effects of recombinant erythropoietin on murine megakaryocytic colony formation in vitro. J Lab Clin Med 1986; 108: 423-429
    PubMedGoogle Scholar
  • 17 Dessypris EN, Gleaton JH, Armstrong OL. Effect of human recombinant erythropoietin on human marrow megakaryocyte colony formation in vitro. Br J Haematol 1987; 65: 265-269
    CrossrefPubMedGoogle Scholar
  • 18 Hoffman R, Straneva J, Yang HH, Bruno E, Brandt J. New insights into the regulation of human megakaryocytopoiesis. Blood Cells 1987; 13: 75-86
    PubMedGoogle Scholar
  • 19 Ishibashi T, Koziol JA, Burstein SA. Human recombinant erythropoietin promotes differentiation of murine megakaryocytes in vitro. J Clin Invest 1987; 79: 286-289
    CrossrefPubMedGoogle Scholar